US specialty pharmacy | Understand the journey before calling it access

We envisage a specialty operations lead, health-system pharmacy director or access programme sponsor asking where a particular referral pathway loses time. The incentive may be fewer repeated administrative tasks, a clearer handover or better use of staff capacity. It must be stated before the study begins. Faster processing is not always better if it conceals unresolved questions, transfers work elsewhere or encourages an unsuitable shortcut through a necessary review.

The first study could cover the administrative path from a complete referral arriving to an agreed operational milestone. The sponsor would specify what complete means, which cases are eligible and which exceptions need professional escalation. Each handover would have a responsible role and a documented reason for waiting. The purpose is to reveal a process that can be improved, not to rank patients by commercial attractiveness.

An authorised partner could supply aggregate queue counts, reason codes, time intervals and a small, appropriately governed case review. We would compare the existing investigation process with a structured PHARMORIS-supported review of the same sample. The proposed outputs would identify missing information, repeated handovers and assumptions requiring confirmation. No live referral decision would be delegated to the software during this initial evaluation.

HHS de-identification guidance provides formal privacy context (HHS, n.d.). The evaluation would begin with the least detailed information capable of answering the operational question, with authority and permitted uses agreed before transfer. Rare conditions and small cohorts can make apparently anonymous records distinctive. The partner’s information-governance team would therefore need to review aggregation and disclosure choices rather than rely on a general promise that names have been removed.

We would stop if the sample cannot distinguish referral completeness from downstream processing, if data access is not authorised or if a proposed improvement weakens an essential review. Continuation would require a verified operational finding and an owner able to change the pathway. A subsequent prospective study could test whether the change persists. The first commercial conversation is about a bounded problem and accountable evaluation, not a claim that PHARMORIS already controls specialty care.

Bring the decision you need to make, the person accountable for it and the evidence you can use. We can then discuss whether a bounded PHARMORIS evaluation is the right next step.